- Home
- A-Z Publications
- Current Pharmaceutical Design
- Previous Issues
- Volume 9, Issue 25, 2003
Current Pharmaceutical Design - Volume 9, Issue 25, 2003
Volume 9, Issue 25, 2003
-
-
Identification and Targeting of Tumor Escape Mechanisms: A New Hope for Cancer Therapy?
Authors: Elke S. Bergmann-Leitner, Elizabeth H. Duncan and Wolfgang W. LeitnerConventional cancer therapy is administered in the form of surgery, radiotherapy or chemotherapy. Immunotherapy is the latest asset to the panel of anti-cancer treatments. This approach appears favorable over the other more conventional methods for various reasons: (1) it is highly specific for cancer cells and, therefore, low toxicity should be expected; (2) it recognizes and eliminates cancer cells regardless of their phase in Read More
-
-
-
Porphyrins as Radiosensitizing Agents for Solid Neoplasms
Authors: M. Schaffer, B. Ertl-Wagner, P. M. Schaffer, U. Kulka, A. Hofstetter, E. Duhmke and G. JoriThe biological effects of radiation affect both neoplastic and normal tissues. The nature and extent of such effects, however, depend on selected biological parameters (e.g., oxygen supply, cell cycle) and can be modified by chemical agents such as radiosensitizers, radioprotectors and chemotherapeutic agents. A precise control of the mode of action of the radiation is important in order to achieve the maximum effect Read More
-
-
-
Bradykinin Antagonists as Anti-Cancer Agents
More LessThe nonapeptide bradykinin is an important growth factor for many cancers. Certain peptide and non-peptide bradykinin antagonists show remarkable anti-cancer activities in both in vitro and in vivo cancer models, especially of lung and prostate cancers. Bradykinin antagonists stimulate apoptosis in cancers by a novel “biased agonist” mechanism: they block intracellular increase of calcium concentration but sti Read More
-
-
-
Src Family Kinases: Potential Targets for the Treatment of Human Cancer and Leukemia
Authors: Markus Warmuth, Robert Damoiseaux, Yi Liu, Doriano Fabbro and Nathanael GrayThe inherited or acquired deregulation of protein kinase activity has been implicated in the pathogenesis of many human diseases, including cancer. Therefore, the inhibition of kinases has been proposed to be a promising strategy in the context of anti-cancer treatment. Many other kinases have been selected as drug discovery targets based on the prevalence of mutations, over-expression and unscheduled activatio Read More
-
-
-
Novel Protein Targeted Therapy of Metastatic Melanoma
Metastatic melanoma patients have a dismal prognosis with poor responsiveness to chemotherapy, radiation therapy and current immunotherapy regimens and a median survival of less than six months. Novel therapies directed at melanoma-selective molecular targets are urgently needed. Based on the frequent constitutive activation of the mitogenactivated protein kinase (MAPK) signaling pathway in malignant melanomas Read More
-
-
-
Renaissance of the Biologically Active Vitamin A Derivatives: Established and Novel Directed Therapies for Cancer and Chemoprevention
Authors: J. Brtko and J. ThalhamerVitamin A and its biologically active derivatives are involved in a complex arrangements of physiological and developmental responses in many tissue of higher vertebrates. Retinoids are natural and synthetic compounds related to retinoic acid that act through interaction with two basic types of nuclear receptors: retinoic acid receptors (RAR α, RARβ and RARγ) and retinoid X receptors (RXRα, RXRβ and RXRγ) as retinoid-i Read More
-
-
-
Recent Developments in the Field of Tumor-Inhibiting Metal Complexes
Authors: M. S. Galanski, V. B. Arion, M. A. Jakupec and B. K. Keppler25 years after the first approval of cisplatin in the clinic against a number of cancer diseases, cisplatin and related compounds continue to be among the most efficient anticancer drugs used so far. Efforts are focused to develop novel platinum- and non-platinum-based antitumor drugs to improve clinical effectiveness, to reduce general toxicity and to broaden the spectrum of activity. In the field of non-platinum compound Read More
-
Volumes & issues
-
Volume 31 (2025)
-
Volume 30 (2024)
-
Volume 29 (2023)
-
Volume 28 (2022)
-
Volume 27 (2021)
-
Volume 26 (2020)
-
Volume 25 (2019)
-
Volume 24 (2018)
-
Volume 23 (2017)
-
Volume 22 (2016)
-
Volume 21 (2015)
-
Volume 20 (2014)
-
Volume 19 (2013)
-
Volume 18 (2012)
-
Volume 17 (2011)
-
Volume 16 (2010)
-
Volume 15 (2009)
-
Volume 14 (2008)
-
Volume 13 (2007)
-
Volume 12 (2006)
-
Volume 11 (2005)
-
Volume 10 (2004)
-
Volume 9 (2003)
-
Volume 8 (2002)
-
Volume 7 (2001)
-
Volume 6 (2000)
Most Read This Month
Article
content/journals/cpd
Journal
10
5
false
en
